title: Recombinant soluble P-selectin glycoprotein ligand-Ig (rPSGL-Ig) attenuates infarct size and myeloperoxidase activity in a canine model of ischemia-reperfusion.
abstract: The role of P-selectin in the process of reperfusion injury was evaluated using a recombinant soluble P-selectin glycoprotein ligand-Ig (rPSGL-Ig) in a canine coronary artery balloon occlusion model. rPSGL-Ig (1 mg/kg) or saline was given as an intravenous bolus 15 min before balloon deflation. Balloon occlusion time was 90 min followed by either 120 min or 7 days reperfusion. Infarct size was significantly reduced in the treatment group when expressed either as percentage of the area at risk or as absolute infarct size. Histological analysis showed that extensive myocardial injury and neutrophil infiltration were reduced by rPSGL-Ig. Myeloperoxidase activity (MPO) was significantly reduced in the risk area in the rPSGL-Ig group. Left ventricular ejection fraction was significantly less impaired during the first 24 h after reperfusion in the rPSGL-Ig group, although there was no difference by 7-day follow-up. Thus, administration of rPSGL-Ig decreases myocardial injury and inflammatory response for at least 7 days after reperfusion of ischemic myocardium.
authors.affiliation: Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, USA. wangk@ccf.org
authors.forename: Kai
authors.initials: K
authors.lastname: Wang
authors.forename: Xiaorong
authors.initials: X
authors.lastname: Zhou
authors.forename: Zhongmin
authors.initials: Z
authors.lastname: Zhou
authors.forename: Khaldoun
authors.initials: K
authors.lastname: Tarakji
authors.forename: Jian Xin
authors.initials: JX
authors.lastname: Qin
authors.forename: Marta
authors.initials: M
authors.lastname: Sitges
authors.forename: Takahiro
authors.initials: T
authors.lastname: Shiota
authors.forename: Farhad
authors.initials: F
authors.lastname: Forudi
authors.forename: Robert G
authors.initials: RG
authors.lastname: Schaub
authors.forename: Anjali
authors.initials: A
authors.lastname: Kumar
authors.forename: Marc S
authors.initials: MS
authors.lastname: Penn
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Topol
authors.forename: A Michael
authors.initials: AM
authors.lastname: Lincoff
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004285:Dogs; D005500:Follow-Up Studies; D008562:Membrane Glycoproteins / Q000008:administration & dosage / Q000494:pharmacology*; D009203:Myocardial Infarction / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control*; D019007:P-Selectin / Q000502:physiology; D009195:Peroxidase / Q000187:drug effects*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D015427:Reperfusion Injury / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D013318:Stroke Volume; D013997:Time Factors
chemical_list: D008562:Membrane Glycoproteins; D019007:P-Selectin; C084882:P-selectin ligand protein; D011994:Recombinant Proteins; D009195:Peroxidase